180 related articles for article (PubMed ID: 35789506)
1. Reply to 'development of severe pemphigus vulgaris following SARS-CoV-2 vaccination with BNT162b2' by Solimani F et al.
Falcinelli F; Lamberti A; Cota C; Rubegni P; Cinotti E
J Eur Acad Dermatol Venereol; 2022 Dec; 36(12):e976-e978. PubMed ID: 35789506
[No Abstract] [Full Text] [Related]
2. Reply to 'Development of severe pemphigus vulgaris following SARS-CoV-2 vaccination with BNT162b2' by Solimani et al.
Martora F; Fabbrocini G; Nappa P; Megna M
J Eur Acad Dermatol Venereol; 2022 Oct; 36(10):e750-e751. PubMed ID: 35679165
[No Abstract] [Full Text] [Related]
3. Development of severe pemphigus vulgaris following SARS-CoV-2 vaccination with BNT162b2.
Solimani F; Mansour Y; Didona D; Dilling A; Ghoreschi K; Meier K
J Eur Acad Dermatol Venereol; 2021 Oct; 35(10):e649-e651. PubMed ID: 34169588
[No Abstract] [Full Text] [Related]
4. Pemphigus vulgaris after SARS-CoV-2 vaccination: A case with new-onset and two cases with severe aggravation.
Akoglu G
Dermatol Ther; 2022 May; 35(5):e15396. PubMed ID: 35187768
[TBL] [Abstract][Full Text] [Related]
5. Immediate reactions after mRNA SARS-CoV-2 vaccination.
Jeimy S; Wong T; Song C
CMAJ; 2021 Dec; 193(48):E1842. PubMed ID: 34772737
[No Abstract] [Full Text] [Related]
6. De novo severe pemphigus vulgaris following SARS-CoV-2 vaccination with BBIBP-CorV.
Saffarian Z; Samii R; Ghanadan A; Vahidnezhad H
Dermatol Ther; 2022 Jun; 35(6):e15448. PubMed ID: 35289040
[No Abstract] [Full Text] [Related]
7. Tuberculosis following two-dose SARS-CoV-2 vaccination with messenger RNA vaccine (BNT162b2) and inactivated virus vaccine (CoronaVac).
Li X; Peng K; Cheng FWT; Lam DCL; Cheung CL; Chui CSL; Lai FTT; Wan EYF; Wong CKH; Ma T; Yum SHH; Chan EWY; Huang JD; Lau CS; Ip MSM; Wong ICK
J Infect; 2023 Mar; 86(3):256-308. PubMed ID: 36539043
[No Abstract] [Full Text] [Related]
8. Autoimmune mucocutaneous blistering diseases after SARS-Cov-2 vaccination: A Case report of Pemphigus Vulgaris and a literature review.
Calabria E; Canfora F; Mascolo M; Varricchio S; Mignogna MD; Adamo D
Pathol Res Pract; 2022 Apr; 232():153834. PubMed ID: 35278817
[TBL] [Abstract][Full Text] [Related]
9. Safety Profile and Low Risk of Disease Relapse After BNT162b2 mRNA SARS-CoV-2 Vaccination in Patients With Rare Rheumatic Diseases.
Fornaro M; Venerito V; Iannone F; Cacciapaglia F
J Rheumatol; 2022 Mar; 49(3):334-335. PubMed ID: 35033998
[No Abstract] [Full Text] [Related]
10. Real-world safety data for the Pfizer BNT162b2 SARS-CoV-2 vaccine, historical cohort study' by Shasha et al.
Scorza FA; Finsterer J
Clin Microbiol Infect; 2022 Mar; 28(3):452-453. PubMed ID: 34839005
[No Abstract] [Full Text] [Related]
11. Prompt onset of Rowell's syndrome following the first BNT162b2 SARS-CoV-2 vaccination.
Gambichler T; Scholl L; Dickel H; Ocker L; Stranzenbach R
J Eur Acad Dermatol Venereol; 2021 Jul; 35(7):e415-e416. PubMed ID: 33725406
[No Abstract] [Full Text] [Related]
12. Pemphigus vulgaris with advanced hypopharyngeal and gastric cancer following SARS-CoV-2 vaccination.
Norimatsu Y; Yoshizaki A; Yamada T; Akiyama Y; Toyama S; Sato S
J Dermatol; 2023 Feb; 50(2):e74-e75. PubMed ID: 35906790
[No Abstract] [Full Text] [Related]
13. Correlation of Immunogenicity and Reactogenicity of BNT162b2 and CoronaVac SARS-CoV-2 Vaccines.
Zhang R; Leung KY; Liu D; Fan Y; Lu L; Chan PC; To KK; Chen H; Yuen KY; Chan KH; Hung IF
mSphere; 2022 Apr; 7(2):e0091521. PubMed ID: 35285250
[TBL] [Abstract][Full Text] [Related]
14. BNT162b2 mRNA SARS-CoV-2 vaccination does not cause upregulation of endothelial activation markers or hypercoagulability: A prospective, single-arm, longitudinal study.
Lim XR; Leung BP; Sum CLL; Lim GH; Chua CG; Tu TM; Ramanathan K; Huang MY; Howe HS; Fan BE
Am J Hematol; 2022 Apr; 97(4):E141-E144. PubMed ID: 35015303
[No Abstract] [Full Text] [Related]
15. Six cases of pityriasis rosea following SARS-CoV-2 vaccination with BNT162b2.
Ramot Y; Nanova K; Faitatziadou SM; Assab DA; Berkun Y; Zlotogorski A
J Dtsch Dermatol Ges; 2022 Aug; 20(8):1123-1124. PubMed ID: 35698860
[No Abstract] [Full Text] [Related]
16. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections.
Desmecht S; Tashkeev A; El Moussaoui M; Marechal N; Perée H; Tokunaga Y; Fombellida-Lopez C; Polese B; Legrand C; Wéry M; Mni M; Fouillien N; Toussaint F; Gillet L; Bureau F; Lutteri L; Hayette MP; Moutschen M; Meuris C; Vermeersch P; Desmecht D; Rahmouni S; Darcis G
Front Immunol; 2022; 13():863554. PubMed ID: 35711445
[TBL] [Abstract][Full Text] [Related]
17. Myocarditis After BNT162b2 and mRNA-1273 Vaccination.
Larson KF; Ammirati E; Adler ED; Cooper LT; Hong KN; Saponara G; Couri D; Cereda A; Procopio A; Cavalotti C; Oliva F; Sanna T; Ciconte VA; Onyango G; Holmes DR; Borgeson DD
Circulation; 2021 Aug; 144(6):506-508. PubMed ID: 34133884
[TBL] [Abstract][Full Text] [Related]
18. Comparison of SARS-CoV-2 Antibody Response Following Vaccination With BNT162b2 and mRNA-1273.
Steensels D; Pierlet N; Penders J; Mesotten D; Heylen L
JAMA; 2021 Oct; 326(15):1533-1535. PubMed ID: 34459863
[TBL] [Abstract][Full Text] [Related]
19. The Safety and Immunogenicity of the mRNA-BNT162b2 SARS-CoV-2 Vaccine in Hemodialysis Patients.
Zitt E; Davidovic T; Schimpf J; Abbassi-Nik A; Mutschlechner B; Ulmer H; Benda MA; Sprenger-Mähr H; Winder T; Lhotta K
Front Immunol; 2021; 12():704773. PubMed ID: 34220867
[TBL] [Abstract][Full Text] [Related]
20. Neutralizing antibody titers elicited by CoronaVac and BNT162b2 vaccines in health care workers with and without prior SARS-CoV-2 infection.
Wolff MJ; Acevedo ML; Núñez MA; Lafourcade M; Gaete-Argel A; Soto-Rifo R; Valiente-Echeverría F
J Travel Med; 2022 May; 29(3):. PubMed ID: 35134229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
